Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Accelerated Phase 1Down Syndrome 1Blast Crisis 1

Interventions

Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Methotrexate 3Cytarabine 3venetoclax 2ponatinib 2merphos 2fludarabine phosphate 2Tacrolimus 2Idarubicin 2Etoposide 2Cyclosporine 2Cyclophosphamide 2Cladribine 2Busulfan 2nilotinib 1midostaurin 1gilteritinib 1bosutinib 1blinatumomab 1asciminib 1Thiotepa 1Sirolimus 1Razoxane 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Melphalan 1Injections 1Imatinib Mesylate 1Gemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × N,N-dicyclohexyl-isoborneol-10-sulfonamide × 30 days × Clear all
NCT03263572 2026-05-20

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
90 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡